Panchsheel Organics Ltd. – Company Report
1. Company Overview
Panchsheel Organics Ltd., established in 1989 and headquartered in Mumbai, is a WHO-compliant, GMP-certified pharmaceutical and biotechnology company with over three decades of industry experience. Promoted by the Turakhia Bros Group, it operates modern manufacturing units in Indore and Ambernath, and an R&D/testing lab in Vasai, Mumbai. The company is engaged in the manufacture and export of a diverse range of Active Pharmaceutical Ingredients (APIs), formulations, nutraceuticals, steroids, probiotics, biofertilizers, and more.
- Incorporated: 1989
- Headquarters: Mumbai, Maharashtra, India
- Manufacturing Facilities: Indore (API, fermentation), Ambernath (specialty chemicals), Vasai (testing lab)
- Certifications: WHO-GMP, ISO standards
- Employees: 201–500
- Promoter Group: Turakhia Bros
- Listed: BSE/NSE
- Export Presence: Strong, with global clientele
2. Products and Services
Panchsheel Organics Ltd. provides a broad range of pharmaceutical and biotechnology products and services:
- APIs & Intermediates: Covering a wide spectrum of therapeutic classes including cardiovascular, anti-infectives, neuropsychiatric, and gastrointestinal.
- Finished Formulations: Tablets, capsules, liquids, and injectables for human and veterinary use.
- Nutraceuticals & Health Supplements: Protein drinks, herbal extracts, Garcinia Cambogia, chromium picolinate, and more.
- Steroids & Hormones: High-purity APIs and finished dosages for regulated markets.
- Probiotics, Enzymes, and Prebiotics: Tailored gut-health and digestive health solutions.
- Biofertilizers and Agri-Biotech: Soil enhancers, bio-stimulants, and eco-friendly crop growth solutions.
- Direct Compression & Pellet Forms: Sustained-release, controlled-release, and enteric-coated products.
- OTC & FMCG Products: Cough and cold relief, painkillers, vitamins, and protein supplements.
- Veterinary APIs & Feed Supplements: APIs and premixes for animal health applications.
- Custom Manufacturing & Exports: Regulatory-compliant contract manufacturing for international clients.
- R&D and Analytical Services: Advanced lab support for formulation, analysis, and microbiology.
The company places strong emphasis on R&D, regulatory compliance, and technology-led differentiation across its product segments.
3. Recent News and Expansion Highlights
Smart Industrial Park, Dhar (Aug 2024):
- Land Allotment: 7 acres on 99-year lease by MPIDC.
- Purpose: New facility for fermentation-based APIs and intermediates.
- Status: Bhumi Pujan scheduled for Aug 28, 2024.
- Strategic Focus: Fermentation technology as a core differentiator.
DMIC Vikram Udyogpuri Biotech Park (Nov 2022):
- Land Allotment: 5 acres on 99-year lease.
- Planned Capacity: Up to 120 TPA for fermentation-based APIs.
- Investment: Up to ₹70 crore (excluding working capital).
- Goal: Geographic diversification and capacity expansion.
These expansions reflect the company’s forward-looking strategy to strengthen its fermentation capabilities, address complex molecule production, and reduce location-specific risk.
4. Financial Performance (FY2025)
| Metric | FY2025 Value |
|---|---|
| Total Revenue | ₹110.25 crore |
| Net Profit (PAT) | ₹13.80 crore |
| Operating Profit | ~₹18 crore |
| Net Profit Margin | 12.5% |
| Earnings Per Share (EPS) | ₹10.47 |
| Dividend Payout % | 31% |
| Debt | Almost debt-free |